Objective: Optimal initial antihypertensive drug therapy in persons with the metabolic syndrome (MetS) is unknown.
The metabolic syndrome (MetS) is a clustering of clinical and biochemical characteristics related to insulin resistance (IR) (1) . It is characterized by hypertension, central obesity, dyslipidemia (high triglycerides, low HDL cholesterol levels), and elevated glucose levels. This syndrome is most commonly found in older adults, in whom obesity and IR have their highest prevalence. It is estimated that upwards of 40% of U.S. adults, age >60 years, now have this disorder (2) .
To date there is no consensus as to which class of antihypertensive medications, if any, is preferred for the treatment of hypertension in patients with the MetS (3). Concerns have been raised that diuretics should not be used since they have unfavorable effects on insulin sensitivity, increase the risk of new onset diabetes mellitus (DM) and adverse clinical outcomes (4) (5) (6) (7) . Calcium channel blockers (CCBs), which are metabolically neutral, and angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs), which improve insulin action (8) (9) (10) , are considered by many to be the initial drugs of choice. Alternatively, the adverse metabolic effects of thiazide diuretics may have little clinical relevance, and it may be that blood pressure (BP) reduction is the most important factor in treating hypertension in all patients whether or not they have MetS (11) .
We addressed these issues in a subgroup analysis of the Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT was a multi-center randomized clinical trial designed to determine whether the occurrence of fatal coronary heart disease (CHD) or nonfatal myocardial infarction (MI) is lower in high-risk hypertensive patients whose antihypertensive treatment began with a calcium channel blocker (CCB) amlodipine (A) or an ACEI (lisinopril [L]) compared to therapy with a thiazide-like diuretic (chlorthalidone [C] ). Since many of the participants enrolled in ALLHAT met the criteria for the MetS, we did a post hoc analysis to evaluate differences in risk of metabolic, cardiovascular disease (CVD), and renal outcomes in nondiabetic participants with or without MetS, according to their initial antihypertensive medication assignment.
METHODS
The ALLHAT cohort consists of men and women aged ≥55 years who had stage 1 or stage 2 hypertension and at least 1 additional risk factor for CHD. Of the 42,418 ALLHAT participants, 33,357 were randomly assigned to therapy with C (n=15,255), A (n=9,048), or L (n=9,054). A fourth arm of the study, which included 9061 participants assigned to an α-blocker (doxazosin), was terminated early (12) and is not considered for these analyses. Details of the ALLHAT study design have been published (13) .
For this analysis, MetS at baseline was defined as the presence of hypertension, which all participants had at study entry, plus the presence of >2 of the following: BMI ≥30 Kg/m 2 , fasting glucose 100-125 mg/dl, fasting triglycerides ≥150 mg/dl, or HDL cholesterol <40 mg/dl in men (<50 mg/dl in women) (1) . BMI was chosen since ALLHAT did not collect data on waist circumference. Other studies of the MetS have used this approach (14) . We excluded participants with a history of DM (n=12,063) and those with baseline fasting glucose levels >126 mg/dl (n=1,105) even though these are considered to be part of the MetS by ATP guidelines (3). Also excluded were 2,674 participants in whom the baseline metabolic syndrome status was undetermined. It was our intent to examine the study questions in those without DM at baseline since we felt that including those with known DM, would largely reflect the findings we have already reported for the DM subgroup in ALLHAT (15) .
Study medications were identicallyappearing C, L, or A capsules. BP lowering was achieved by titrating the dose of the blinded study drug and adding open-label step 2 (atenolol, clonidine, or reserpine) or step 3 (hydralazine) agents, as necessary to obtain a BP of < 140/90 mmHg (13) .
Follow-up visits were conducted at 1, 3, 6, 9, and 12 months, and every 4 months thereafter. The primary outcome was a composite of fatal CHD or nonfatal myocardial infarction.
Four major prespecified secondary outcomes were (1) allcause mortality, (2) fatal and nonfatal stroke, (3) combined CHD (primary outcome, or coronary revascularization, or hospitalized angina), and (4) combined cardiovascular disease (combined CHD, or stroke, or treated angina, or heart failure (HF [fatal, hospitalized, or treated non-hospitalized]) or peripheral arterial disease). ESRD (dialysis, renal transplant or kidney disease death) and individual components of the major outcomes, including HF, were also prespecified.
Standardized procedures were employed for reporting and validating study outcomes and were previously detailed (16). Although not pre-specified, we also calculated changes in fasting glucose (FG) levels and the incidence of DM (FG >126 mg/dl) in the 3 treatment groups during follow-up. Glomerular filtration rate (GFR) was estimated using the simplified MDRD equation (17) .
Data were summarized as mean (+SD) for continuous variables and number of subjects (percentage) for categorical variables. Baseline characteristics were compared in participants with and without MetS using the Z-test for significance testing of continuous covariates and contingency table analyses for categorical data. Outcomes were analyzed using an intention-to-treat approach. The proportional hazards (PH) model was used to determine time to event hazard ratios (hereafter called relative risks [RRs] ) and 95% CIs. Cox test assumptions were examined using log-log plots and tests of treatment by time (time-dependent) interaction terms. When the assumptions were violated, a two-by-two table was used to estimate relative risk. Heterogeneity of treatment effects across MetS was examined by testing for treatment-covariate interaction using a p<0.05. Given the many subgroup and interaction analyses that were done, statistical significance at the p<0.05 level should be interpreted with caution.
All statistical analyses were carried out using STATA version 8.0.
RESULTS
Baseline characteristics of the cohort, categorized by the presence and absence of MetS, are shown in Table 1 . As compared to those without MetS, participants with MetS were younger and were more likely to be white, female, on antihypertensive treatment, and to have prevalent CHD or prior coronary revascularization. They had slightly more years of education, lower systolic BP, higher BMI, lower high density lipoprotein cholesterol and higher FG and triglyceride levels. They were less likely to smoke or to have electrocardiographic left ventricular hypertrophy (LVH). The mean duration of follow-up was 4.9 years (maximum 8.1 years). Losses to follow-up were minimal; 99% of expected person-years were observed (Appendix Figure  1 [available at http://care.diabetesjournals.org]). Figure  2 ). Among participants with MetS, systolic (S) BP at years 1 through 4 were higher for those on A compared with those on C by approximately 1-1.5 mmHg, a statistically significant difference only at year 1 (p=0.007).
Blood Pressure Control (Appendix
Diastolic (D) BP was 0.5-0.9 mmHg lower at all annual visits in the group assigned to A. Participants assigned to L had 1.5-3 mmHg higher SBP compared with those assigned to C at all annual visits (statistically significant at year 1 [p<0.001], year 2 [p<0.001], and year 3 [p=0.03]). Diastolic BP was non-statistically significantly higher at years 1 through 3.
Among participants without MetS, SBP was consistently higher among those assigned to A versus those assigned to C (statistically significant except at year 2 [p=0.44]). SBP was also higher among those assigned to L versus those assigned to C (p<0.001 for all years). DBP tended to be slightly higher among those assigned to L, and the differences were statistically significant at year 1 (p=0.001) and year 2 (p=0.02). DBP was slightly lower among those assigned to A compared with those assigned to C (p<0.02 at all years except for year 2 ([p=0.06]). (Table 2) . At the end of 4 years, there were no statistically significant differences in total cholesterol (TC) between treatment groups among those with MetS. Among those without MetS, TC levels were lower in the A (mean 194.7 mg/dl) or L (mean=195.8 mg/dl) groups as compared to C (mean=199.2 mg/dl) group (p < 0.001 and p<0.05, respectively). For both those with and without MetS, potassium levels were on average higher at both 2 and 4 years in the A and L groups as compared to C (p<0.001). Fasting glucose levels rose in all three treatment groups during the trial. In those with MetS, FG levels at Year 2 were 3-7 mg/dl lower in the A and L groups compared to those on C (by 2-3 mg/dl in those without MetS). At year 4, those on L still had a lower FG compared to those on C. These findings translated into a DM incidence (FG>126 mg/dl) at 4 years of 17.1% in those assigned to C therapy who had MetS and 16.0% for those assigned to A (p = 0.49). For those treated with L the corresponding DM incidence was 12.6% (p<0.05 versus C). For those without MetS, incident DM at Year 4 follow-up was lower in those treated with A (4.2%) and L (4.7%) as compared to C (7.7%, p<0.05 for both comparisons)
Biochemical Changes
. Estimated GFR was generally slightly lower for participants with MetS compared with participants without MetS. For participants with MetS, estimated GFR was higher at 2 years and 4 years among participants assigned to A compared with those assigned to C. Estimated GFR was similar at 2 years and 4 years for participants assigned to L compared with those assigned to C. Treatment group comparisons were similar in those without MetS.
CVD & Renal Endpoints by Treatment
Group: Figure 1 . shows the unadjusted RRs for each endpoint comparing the A to C and L to C groups for those with and without the MetS separately.
In those with MetS, there were no significant differences in the primary endpoint (CHD [nonfatal MI or CHD death]) for either A vs. C (RR=0.96, 95% CI=0.79-1.16) or L vs. C (RR=1.05, 95% CI=0.88-1.27). These results were similar to those without MetS (p for interaction -NS). The 6-year CHD rates (per 100) for those in the C, A, and L groups among those with MetS were 9.6, 8.8., and 10.5 and among those without MetS were 9.0, 9.6, and 9.6, respectively. For the A vs. C comparison, there were no treatment group differences in the secondary endpoints of combined CVD, all-cause mortality, stroke, or ESRD, and the results were similar in those with and without MetS (p for interaction -NS). In those without the MetS, A vs C treatment was associated with significantly more HF (RR=1.55, 95% CI=1.25-1.91) whereas for those with MetS there was no difference (RR=1.09, 95% CI=0.85-1.38) (p for interaction = 0.03). Those with the MetS assigned to L compared to C were significantly more likely to experience HF (RR=1.31, 95% CI=1.04-1.64) and combined CVD (RR=1.19, 95% CI=1.07-1.32). These results were not statistically different for those without MetS (p for interaction -NS).
Within each treatment group (C, L or A) there were no statistically significant differences in combined CVD between those who developed incident DM vs those who did not in those with and without MetS (Appendix Figure 3) .
However, there appeared to be a greater separation between those with and without incident DM in the A or L groups vs those treated with C.
DISCUSSION
In this study of non-diabetic hypertensive adults with and without the MetS we found that CHD, all cause mortality, stroke, and renal outcome rates did not differ significantly between those whose initial treatment was a thiazide-type diuretic compared those treated first with a CCB or an ACEI. However, in participants with MetS, those treated with a diuretic had a lower risk of HF and combined CVD compared to those treated with ACEI. There were no differences in outcomes between diuretic and CCB in those with MetS, but participants without MetS had a higher risk of HF with CCB therapy. These results are consistent with the overall results of the ALLHAT study (16) , as well as in the diabetic subgroup of ALLHAT participants (15) , suggesting that diuretics are the preferred initial treatment for HTN in older persons with the MetS compared with ACEI and CCBs, despite the higher incidence of new DM for the C group.
Even without clinical outcome data, several reviews suggest that drugs which block the renin-angiotensin-aldosterone system (ACEI/ARBs) should be the treatment of choice for hypertension in those with MetS (5, (18) (19) (20) (21) (22) (23) .
The basis for these recommendations is that the MetS is characterized by obesity and IR, conditions which are associated with increased inflammatory markers, endothelial dysfunction, and elevated levels of angiotensin. ACEI/ARBs which improve endothelial dysfunction (24) , block the metabolic effects of angiotensin (25) , lower the levels of several inflammatory markers (26) , and improve insulin sensitivity should therefore have theoretical advantages in these patients. Our results show that despite these theoretical considerations, ACEI provided no advantage over thiazide-type diuretics in prevention of CV outcomes. These results are consistent with those of the Blood Pressure Lowering Treatment Trialists' Collaboration which reported no significant differences in CHD, stroke or CHF outcomes between ACEI therapy and diuretic therapy (with or without beta-blockers) in hypertensive adults with or without diabetes mellitus (27) . Likewise, the recently-reported DREAM study showed no benefit of ACEI therapy over placebo for preventing glucose metabolic disturbances (28) .
Many researchers believe that it is degree of BP reduction achieved that is the primary determinant of clinical outcomes, not which drug is used to attain the reduction (11) . Since the BP differences seen between treatment groups for those with and without the MetS were not greater than those observed over all in ALLHAT, we feel that any differences in benefit attributable to BP reduction is likely to apply equally to both subgroups.
In all treatment groups, with or without MetS, FG levels increased during the trial. Those with MetS treated with C had higher FG levels at 2 years than those treated with A or L. By Year 4, however, there was no difference between those treated with A and those treated with C, while those treated with L had ~ 4 mg/dl lower values. In spite of this unfavorable biochemical finding the change in FG levels did not adversely impact CVD outcomes, findings similar to what we found in the non-diabetic cohort of ALLHAT (15) . The possibility has been raised that had ALLHAT been extended to 10 or 15 years of follow up, the negative effect of elevated FG levels and the dyslipidemia associated with diuretic use would have become evident (29) . The recent report from the 14 year follow up of the SHEP Study does not support this argument (30) . Glucose elevation observed during C therapy in that study was minimal. In those assigned to C who developed DM, the risk of CVD mortality was similar to those who did not develop DM (HR 1.04 [95% confidence interval, 0.75-1.46]), whereas in those assigned to placebo who developed DM, the CVD mortality risk was higher compared to those who did not develop DM (HR 1.56 [95% confidence interval 1.12-2.18]).
The current study has important strengths. Compared to other HTN trials, ALLHAT is the largest and provides much greater statistical power to recognize associations and differences. Considerable attention was paid to quality assurance. All laboratory tests were done in a certified central laboratory. The study was conducted in a variety of practice environments (academic, HMO, private practice, Veterans Administration clinics), reflective of medical practice across the United States. The cohort for this analysis was created so as to exclude people with DM, thereby excluding the confounding effects of elevated glucose levels on clinical outcomes. There are, of course, limitations. Our analyses are post hoc since the MetS was not a pre-designated subgroup analysis. Since entry into ALLHAT required the presence of HTN and one other CVD risk factor, participants not having an eligibility risk factor that is a MetS component (low HDL) were inevitably more likely to have other eligibility risk factors (e.g., LVH or smoking). This may explain why the rates of some of the endpoints were lower in participants with the MetS compared to those without it, something we would not have expected. Because of its large simple trial design, several factors that are part of the definition of MetS or segregate with the MetS, such as inflammatory factors, waist circumference and urinary albumin were not recorded in ALLHAT. Last, there is lack of uniformity and consensus on the definition of the MetS, making it difficult to directly compare our results to other studies using different definitions.
In conclusion, thiazide-like diuretic initial therapy for hypertension offers similar and in some instances possibly superior CVD and renal outcomes in older hypertensive adults with MetS, as compared to treatment with CCBs and ACEI. This was so in spite of the mildly increased FG levels and higher level of incident DM in those treated with the thiazide-like diuretics as compared to the other two medications. These findings are consistent with those in the overall ALLHAT cohort and in the subgroup with DM, as previously reported (15, 16) .
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